Related Experiment Video

Updated: Jun 27, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent

Nobuo Cho1, Yu Momose

  • 1Medicinal Chemistry Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka 532-8686, Japan. Cho_Nobuo@takeda.co.jp

Current Topics in Medicinal Chemistry
|December 17, 2008
PubMed

Insights

New therapies targeting peroxisome proliferator-activated receptor gamma (PPARgamma) show promise for treating type 2 diabetes and obesity. Research is accelerating the development of novel insulin-sensitizing agents to combat metabolic diseases.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Molecular Biology

Background:

  • Metabolic diseases like type 2 diabetes and obesity are a growing health concern in industrialized nations.
  • Peroxisome proliferator-activated receptor gamma (PPARgamma) is a key regulator of glucose and lipid metabolism.
  • PPARgamma is a validated drug target for insulin sensitization.

Purpose of the Study:

  • To review the discovery and development of thiazolidinediones (TZDs) and other PPARgamma agonists.
  • To provide an overview of PPARgamma's role in metabolic homeostasis.
  • To highlight novel PPARgamma ligands and therapeutic strategies for type 2 diabetes.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of the pharmacological profiles of various PPARgamma agonists.
  • Exploration of emerging concepts and evidence in PPARgamma-targeted drug development.

Main Results:

  • Thiazolidinediones (TZDs) were the first class of PPARgamma agonists with clinical success.
  • Numerous novel PPARgamma agonists, including dual/pan agonists and selective modulators (SPPARgammaMs), are under development.
  • Despite challenges, PPARgamma-targeted agents demonstrate potential for improved anti-diabetic therapies.

Conclusions:

  • PPARgamma remains a promising target for developing innovative treatments for type 2 diabetes.
  • Ongoing research is yielding diverse pharmacological profiles and new therapeutic approaches.
  • Further development of PPARgamma ligands could lead to more effective anti-diabetic agents.

More Related Videos

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...